Alembic Pharmaceuticals gets USFDA tentative approval for Darolutamide 300mg — a $3.15 billion prostate cancer market
Alembic Pharmaceuticals Limited has received tentative approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Darolutamide Tablets, 300 mg — a generic equivalent to Bayer HealthCare Pharmaceuticals’ branded product …